258 HORIZON-01: a phase I–III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC).
Saved in:
| Title: | 258 HORIZON-01: a phase I–III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). |
|---|---|
| Authors: | Sanjay, Popat1,2 (AUTHOR), Adam, Januszewski3 (AUTHOR), Laura, Cove-Smith4,5 (AUTHOR), Shobhit, Baijal6 (AUTHOR), Georgios, Imseeh7 (AUTHOR), Carl, Gay8 (AUTHOR), Keith, Kerr9 (AUTHOR), Terufumi, Kato10 (AUTHOR), Luis, Paz-Ares11 (AUTHOR), Caicun, Zhou12 (AUTHOR), Karl, Redhead13 (AUTHOR), Elizabeth, Theogaraj13 (AUTHOR), Sarah M., Shagan14 (AUTHOR), Benjamin J., Solomon15 (AUTHOR) |
| Source: | Lung Cancer (01695002). 2025 Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
